Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers by Ozkan-Dagliyan, Irem et al.
ArticleLow-Dose Vertical Inhibition of the RAF-MEK-ERK
Cascade Causes Apoptotic Death of KRAS Mutant
CancersGraphical AbstractHighlightsd Vertical inhibition of the RAF-MEK-ERK cascade drives
apoptotic cell death rather than cytostasis
d RAF+ERK inhibition induces powerful synergy, enabling
effective treatment at low doses
d Concurrent RAF+ERK inhibition renders treated cells
insensitive to compensatory ERK reactivation
d Concurrent RAF+ERK inhibition induces MET and silences
the MYC-dependent transcriptomeOzkan-Dagliyan et al., 2020, Cell Reports 31, 107764
June 16, 2020 ª 2020 The Author(s).
https://doi.org/10.1016/j.celrep.2020.107764Authors
Irem Ozkan-Dagliyan, J. Nathaniel Diehl,
Samuel D. George, ..., Kris C. Wood,
Adrienne D. Cox, Channing J. Der
Correspondence
cjder@med.unc.edu
In Brief
Ozkan-Dagliyan et al. apply a chemical
screen and identify concurrent inhibition
of RAF and ERK as the most potent
combination that causes low-dose
apoptotic death of KRAS mutant
pancreatic cancer. This vertical inhibition
combination is resistant to loss of
negative feedback mechanisms that
reactivate ERK and potently suppresses
diverse ERK-dependent processes.ll
OPEN ACCESS
llArticle
Low-Dose Vertical Inhibition
of the RAF-MEK-ERK Cascade Causes
Apoptotic Death of KRASMutant Cancers
Irem Ozkan-Dagliyan,1 J. Nathaniel Diehl,2 Samuel D. George,3,4 Antje Schaefer,1 Bjoern Papke,4 Kathleen Klotz-Noack,5
Andrew M. Waters,4 Craig M. Goodwin,4 Prson Gautam,6 Mariaelena Pierobon,7 Sen Peng,8 Thomas S.K. Gilbert,9
Kevin H. Lin,10 Onur Dagliyan,11 Krister Wennerberg,6 Emanuel F. Petricoin III,7 Nhan L. Tran,13 Shripad V. Bhagwat,14
Ramon V. Tiu,14 Sheng-Bin Peng,14 Laura E. Herring,9 Lee M. Graves,1 Christine Sers,5,15,16 Kris C. Wood,10
Adrienne D. Cox,1,4,12 and Channing J. Der1,2,4,5,17,*
1Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
2Curriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
3Department of Computer Science, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
4Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
5Charite´ Universita¨tsmedizin Berlin, Institute of Pathology, Laboratory of Molecular Tumor Pathology and Systems Biology, 10117 Berlin,
Germany
6Institute for Molecular Medicine Finland, University of Helsinki, 00290 Helsinki, Finland
7Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA 20110, USA
8Departments of Cancer and Cell Biology, Translational Genomics Research Institute, Phoenix, AZ 85004, USA
9UNC Michael Hooker Proteomics Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
10Department of Pharmacology and Cancer Biology, Duke University, Durham, NC 27710, USA
11Department of Neurobiology, Harvard Medical School, Boston, MA 02115, USA
12Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
13Departments of Cancer Biology and Neurosurgery, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA
14Eli Lilly and Company, Indianapolis, IN 46285, USA
15German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
16Berlin Institute of Health (BIH), Anna-Louise-Karsch-Str. 2, 10178 Berlin, Germany
17Lead Contact
*Correspondence: cjder@med.unc.edu
https://doi.org/10.1016/j.celrep.2020.107764SUMMARYWe address whether combinations with a pan-RAF inhibitor (RAFi) would be effective in KRAS mutant
pancreatic ductal adenocarcinoma (PDAC). Chemical library and CRISPR genetic screens identify combina-
tions causing apoptotic anti-tumor activity. Themost potent combination, concurrent inhibition of RAF (RAFi)
and ERK (ERKi), is highly synergistic at low doses in cell line, organoid, and rat models of PDAC, whereas
each inhibitor alone is only cytostatic. Comprehensive mechanistic signaling studies using reverse phase
protein array (RPPA) pathwaymapping and RNA sequencing (RNA-seq) show that RAFi/ERKi induced insen-
sitivity to loss of negative feedback and system failures including loss of ERK signaling, FOSL1, and MYC;
shutdown of the MYC transcriptome; and induction of mesenchymal-to-epithelial transition. We conclude
that low-dose vertical inhibition of the RAF-MEK-ERK cascade is an effective therapeutic strategy for
KRAS mutant PDAC.INTRODUCTION
The genetic basis of pancreatic ductal adenocarcinoma (PDAC)
is well established (Ryan et al., 2014), yet current standards of
care comprise conventional cytotoxic drugs rather than targeted
therapies. Among the fourmajor genetic alterations inPDAC, only
KRAS functions as an oncogene. Given the >95% KRAS muta-
tion frequency in PDAC and substantial experimental evidence
that KRAS is essential for PDAC maintenance (Collins et al.,
2012; Ying et al., 2012), KRAS is the most attractive target for
therapeutic intervention in this disease (Waters and Der, 2018).This is an open access article under the CC BY-NDespite significant recent progress in developing direct inhib-
itors of mutant KRAS (Janes et al., 2018; Ostrem and Shokat,
2016), with two now under clinical evaluation, these are selective
for KRASG12C, a mutant that is found infrequently (only 2%) in
PDAC (Cox et al., 2014). Inhibitors of KRAS effector signaling
remain promising KRAS-targeted therapies (Papke and Der,
2017; Ryan and Corcoran, 2018). Of the multitude of effectors,
substantial experimental studies and PDAC patient data support
the key role of the RAF-MEK-ERK mitogen-activated protein
kinase (MAPK) cascade in driving KRAS-dependent PDAC
growth. Mutationally activated BRAFV600E can phenocopyCell Reports 31, 107764, June 16, 2020 ª 2020 The Author(s). 1
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
(legend on next page)
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static PDAC (Collisson et al., 2012), and BRAF mutations are
found in 50% of the rare PDAC that are KRAS wild type (WT)
(TCGA, 2017). Further, an effector small interfering RNA (siRNA)
screen demonstrated that KRAS-dependent cancers are driven
largely by RAF (Yuan et al., 2018). These observations support
the RAF-MEK-ERK cascade as the key effector pathway driving
KRAS-dependent PDAC. However, to date, therapeutic target-
ing of MEK in KRAS mutant lung cancer demonstrated limited
to no efficacy in patients (Blumenschein et al., 2015; Ja¨nne
et al., 2017). Challenges to the effective use of inhibitors of
ERK MAPK signaling include toxicity in normal cells (Blasco
et al., 2011) and adaptive responses to inhibitor treatment, re-
sulting in ERK reactivation and bypass of inhibitor action (Dun-
can et al., 2012).
Another challenge in targeting the ERK MAPK cascade is
determining which level of the three-tiered kinase cascade will
provide the most effective and long-term therapeutic response.
At the top of the pathway are the three highly related RAF iso-
forms—ARAF, BRAF, and CRAF/RAF1—that exhibit distinct
roles in RAS-driven cancers (Desideri et al., 2015). BRAF-selec-
tive inhibitors caused paradoxical activation of ERK signaling in
RAS mutant cancers (Hatzivassiliou et al., 2010; Poulikakos
et al., 2010). Pan-RAF inhibitors (RAFis) overcome paradoxical
activation and showed greater activity in KRAS mutant cancers
(Peng et al., 2015; Yen et al., 2018). However, genetic deletion
studies in Kras-driven mouse models argue that pan-RAF inhibi-
tionmay be limited by normal cell toxicity and that a CRAF-selec-
tive strategy may provide a tumor-selective therapy (Blasco
et al., 2011; Karreth et al., 2011). In contrast, Craf deficiency in
a KrasG12D-driven PDACmodel had no inhibitory effect on tumor
development or progression (Eser et al., 2013). Thus, the role of
specific RAF isoforms in KRAS-driven oncogenesis may be
highly tissue selective.
Recently, we addressed the limitations of RAFis and MEK in-
hibitors (MEKis) by using ERK1/2-selective inhibitors in KRAS
mutant PDAC (Hayes et al., 2016). We found that ERK1/2 inhibi-
tion suppressed PDAC growth and that sensitivity correlated
with ERK inhibition-mediated loss of MYC protein. In search of
combinations to enhance the anti-tumor efficacy of inhibitorsFigure 1. Concurrent Inhibition of All RAF Isoforms Diminishes PDAC
(A) PDAC cell lines were infected by lentivirus vectors encoding nonspecific (NS)
Colonies were stained by crystal violet 10 days after plating. Data are presented
individual graph. Adjusted p values are fromDunnett’s multiple comparison test. A
0.8883, BRAF-sh2 = 0.0592, CRAF-sh1 = *, 0.0024, CRAF-sh2 = 0.6350), (KRAS-
0.8788, BRAF-sh2 = 0.1990, CRAF-sh1 = 0.0539, CRAF-sh2 = 0.2738), (KRAS-s
BRAF-sh1 = *, 0.0103, BRAF-sh2 = ****, < 0.0001, CRAF-sh1 = ****, < 0.0001, CRA
ARAF-sh2 = 0.7500,BRAF-sh1 = 0.9977,BRAF-sh2 = ****, < 0.0001,CRAF-sh1 = *
(ARAF-sh1 = 0.5520, ARAF-sh2 = **, 0.0051, BRAF-sh1 = 0.2316, BRAF-sh2 = **,
0.3213, ARAF-sh2 = ****, < 0.0001, BRAF-sh1 = 0.0586, BRAF-sh2 = **, 0.0025,
(B) PDAC cell lines were treated with RAFi (0.04–10 mM, 72 h). Cell lysates were
sentative of three independent experiments.
(C) PDAC cell lines were treated with RAFi (0.01–2.5 mM, 72 h). Proliferation was m
independent experiments. Error bars are shown as ± SEM.
(D) CRISPR screen. PDAC cell lines were infected with the CRISPR library and tr
replicate samples). The enrichment score indicates either enrichment (red) or dep
control.
(E) Cell lines were infected by lentivirus vectors encoding NS or two distinct ARA
measured by Calcein AM cell viability assay. Data are the mean average of threeof the RAF-MEK-ERK cascade, we identified inhibitors that
target a spectrum of functionally diverse proteins that synergized
with a pan-RAFi to cause apoptotic death. Surprisingly, the
strongest synergistic and apoptotic activity resulted from con-
current inhibition of RAF and ERK, which was more effective
than concurrent inhibition of either RAF and MEK or MEK and
ERK and was particularly striking at low doses. We have delin-
eated a multi-faceted mechanistic basis for the anti-tumor po-
tency of this vertical inhibition of the ERK MAPK cascade.
RESULTS
ARAF, BRAF, and CRAF Contribute to Growth of KRAS
Mutant Pancreatic Cancer
Previous studies evaluating the three RAF serine/threonine ki-
nase isoforms suggested distinct tissue-specific dependencies
in the development of KRAS-driven cancers, with Craf critical
for Kras-driven lung cancer (Blasco et al., 2011; Karreth et al.,
2011) but not pancreatic cancer (Eser et al., 2013). We previously
determined that a panel of nine conventional KRAS mutant
PDAC lines exhibited KRAS-dependent growth (Hayes et al.,
2016). To further address the role of RAF isoforms in the growth
of KRAS mutant PDAC, we additionally verified the KRAS-
dependent growth of four KRAS mutant cell lines established
from patient-derived xenograft (PDX) PDAC tumors (Figures
1A, S1A, and S1B). Applying previously characterized small
hairpin RNA (shRNA) vectors for selective suppression of
ARAF,BRAF, orCRAF (Freeman et al., 2013), we found that sup-
pression of any RAF isoform alone was sufficient to partially
impair growth of all six KRAS mutant PDX PDAC cell lines (Fig-
ures 1A, S1C, and S1D), demonstrating that eachRAF gene con-
tributes to KRAS-dependent PDAC growth, with the general hi-
erarchy of significance CRAF>BRAF>ARAF. This finding is
similar to that made by McCormick and colleagues, where con-
current siRNA suppression of all three RAF genes was required
to cause an equivalent suppression of growth of KRAS mutant
cell lines as seen with KRAS suppression (Yuan et al., 2018).
This finding suggested that optimal inhibition of RAF in KRAS
mutant PDAC will require a pan-RAFi. We utilized the pan-RAFi
LY3009120, which displays potent nanomolar inhibition of allGrowth
control or distinct shRNAs targeting ARAF, BRAF, CRAF, or KRAS sequences.
as median. All p values shown are in comparison to the vehicle control for the
djusted p values: Pa01C (ARAF-sh1 = 0.6792,ARAF-sh2 = 0.6726,BRAF-sh1 =
sh = ***, 0.0010). Pa02C (ARAF-sh1 = 0.7153, ARAF-sh2 = 0.0692, BRAF-sh1 =
h = **, 0.0068). Pa14C (ARAF-sh1 = ****, < 0.0001, ARAF-sh2 = ****, < 0.0001,
F-sh2 = ****, < 0.0001, KRAS-sh = ****, < 0.0001). Pa16C (ARAF-sh1 = 0.9995,
***, < 0.0001,CRAF-sh2 = ****, < 0.0001,KRAS-sh = ****, < 0.0001). MIA PaCa-2
0.0076, CRAF-sh1 = **, 0.0086, CRAF-sh2 = **, 0.0098). PANC-1 (ARAF-sh1 =
CRAF-sh1 = ****, < 0.0001, CRAF-sh2 = ****, < 0.0001).
immunoblotted to determine levels of the indicated proteins. Data are repre-
easured by Calcein AM cell viability assay. Data are the mean average of three
eated with vehicle control or RAFi (w2, 2 weeks; w4, 4 weeks; a and b indicate
letion (blue) of the indicated genes in cells treated with RAFi relative to vehicle
F shRNAs (72 h) and treated with RAFi (0.01–2.5 mM, 120 h). Proliferation was
technical replicates. Error bars are shown as ± SEM. Summary of GI50 values.
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Figure 2. Identification of Synergistic Drug Combinations That Enhance ERK MAPK Inhibitor Cytotoxicity
(A) Cell lines were treated with a 525-inhibitor library with or without RAFi (2 mM, 72 h). Cell death was measured by CellTox Green. Drug sensitivity score (dDSS)
was used to quantify inhibitor responses and plotted as red (>additive), blue (<additive) or white (no effect).
(legend continued on next page)
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viously (Hatzivassiliou et al., 2010; Poulikakos et al., 2010), the
mutant BRAF-selective inhibitor vemurafenib caused dose-
dependent paradoxical activation rather than inactivation of
ERK in KRAS mutant PDAC cells (Figure S1E). In contrast, treat-
ment with RAFi caused dose-dependent inhibition of ERK, with
IC50 values ranging from 0.20 to 2.37 mM (Figures 1B and S1F;
Table S1A).
We next determined the effects of RAFi treatment on the
growth of a panel of KRASmutant PDAC cell lines (Figure 1C; Ta-
bles S1A, S1C, and S1D). Defining sensitivity as a GI50 of
<2.5 mM, a concentration where pERK is suppressed, we
observed that four cell lines were sensitive (GI50 0.20–
2.41 mM), and five lines were resistant (GI50 > 2.5 mM) after
3 days of treatment. However, after a 5-day treatment, only
two lines remained resistant. Interestingly, sensitivity to RAFi
did not correspond to sensitivity to either the MEK1/2-selective
inhibitor selumetinib or the ERK1/2-selective inhibitor
SCH772984 (Hayes et al., 2016) (Table S1A). These distinct sen-
sitivities indicate that inhibition of the ERK MAPK cascade at
different levelsmay not have equivalent consequences, although
off-target activities of each inhibitor and other factors (e.g., mode
of action, binding affinity) may contribute to these differences.
To identify a genetic basis for sensitivity and resistance to
RAFi, we performed a CRISPR screen targeting the druggable
genome in the presence of a sublethal (GI30) concentration of
RAFi in a sensitive (Pa02C) and a resistant (Pa01C) PDAC line.
We identified genes whose loss increased or decreased sensi-
tivity to RAFi (Figures S1G–S1I). Shown in the heatmap are 45
genes where three or more short guide RNAs (sgRNAs) scored
in the top 25% of ranked hits on average for each condition;
for themajority of these, their loss increasedRAFi sensitivity (Fig-
ure S1I). Among the 37 genes in that category are some identified
previously to regulate sensitivity to MEKis/ERK inhibitors (ERKis)
(e.g., HDAC7, PIK3CB, and PDGFRB) (Anderson et al., 2017;
Sun et al., 2014). Surprisingly, ARAF was among the top 10%
of hits (Figure 1D), with stable suppression of ARAF causing up
to a 4-fold shift in GI50 in both RAFi-sensitive and RAFi-resistant
PDAC cell lines (Figures 1E and S1J). Suppression of BRAF or
CRAF also increased sensitivity to RAFi (Figure S1K). These re-
sults may reflect that non-kinase functions are not blocked by
an ATP-competitive inhibitor of kinase activity.
Chemical Library Screen Identifies Synergistic ERK
MAPK Vertical Inhibition Combinations
To determine if co-treatment with other signaling inhibitors could
overcome RAFi de novo resistance, we utilized a 525-compound
chemical library comprising approved or clinical candidate
oncology inhibitors (Pemovska et al., 2013) (Table S1E) in a panel
of 20 KRAS mutant human or mouse PDAC cell lines (Fig-
ure S2D). We applied both viability (CellTiter-Glo) and cytotox-
icity (CellTox Green) assays to identify drug combinations that
enhanced RAFi growth inhibitory or cytotoxic activity, respec-(B–D) Pa02C and Pa16C were treated with RAFi (0.01–2.5 mM) alone or in combin
mM) (D) for 120 h. Proliferation wasmeasured by Calcein AMcell viability assay. Re
shown (left). Red, synergy; green, antagonism; white, no effect. Averaged dose
cates) are shown (right). Error bars are ± SEM. Synergyavg = average bliss synertively. Combinations were identified as synergistic when the
delta drug sensitivity score (DSS) [DSS (drug+RAFi)  DSS
(drug alone)] was >5 or antagonistic when deltaDSSwas%5 (Pe-
movska et al., 2013). Synergy or antagonism identified in two or
more cell lines is shown for cytotoxicity and viability assays (Fig-
ures 2A and S2A). Reflecting the genetic heterogeneity of PDAC
(Waters and Der, 2018), we observed significant cell line vari-
ability in drug sensitivity. The screens identified multiple chemi-
cally distinct inhibitors of the same functional class of proteins.
We focused on the RAFi combinations identified in the cyto-
toxic assay (Figure 2A). As expected, we identifiedmultiple inhib-
itors of PI3K-AKT-mTOR signaling in the viability screen and to a
significantly lesser degree in the cytotoxicity screen (Figures 2A
and S2A) (Engelman et al., 2008). Multiple inhibitors of EGFR/
HER2 receptor tyrosine kinases, HSP90, histone deacetylases,
and microtubule organization were also able to cause cell death
when combined with RAFi.
Unexpectedly, we found that cytotoxic RAFi combinations
included MEKis or ERKis, but not RAFis. Similarly, combinations
with the MEKi trametinib or the ERKi SCH772984 were with
EGFR/HER2, pan-RAF, and ERK, but not other MEKis (Fig-
ure S2B), or with EGFR/HER2 inhibitors, pan-RAFis, and MEKis,
but not other ERKis (Figure S2C), respectively. These findings
suggest that for a vertical combination to be synthetic lethal,
each inhibitor must target a distinct node of the RAF-MEK-ERK
pathway (Figure S2E).
We performed Bliss analyses to determine whether the inhib-
itory activities of each combination were additive or synergistic;
Bliss scores greater than 1.0 indicate synergy. Concurrent inhibi-
tion of RAF and ERK (designated RAFi/ERKi hereafter) not only
caused cytotoxicity in RAFi-sensitive KRAS mutant PDAC lines
in a dose-dependent manner, but also sensitized RAFi-resistant
cells (Figures 2B and S3A). This combination was highly syner-
gistic, with average synergy scores of 12.5 and 15.5 for Pa02C
and Pa16C cell lines, respectively (Table S1F), particularly at
lower concentrations of each inhibitor. In ERKi-resistant Pa16C
cells, the GI50 for RAFi alone was 839 nM, whereas it was only
5 nM when combined with a low dose of ERKi (80 nM) (Table
S1D). Thus, 168-fold less RAFi was able to produce similar effi-
cacy when used as a component of vertical pathway inhibition.
Interestingly, the ERKi screen did not identify BRAF-selective
inhibitors (Figure S2C), and BRAF inihibitors (BRAFis) in combi-
nation with ERKis resulted in no significant enhancement in ac-
tivity (Figure S3B; Table S1I). This result supports the require-
ment to inhibit all RAF isoforms to disrupt KRAS signaling to
ERK (Figures 1A, S1C, and S1D).
Consistent with the requirement to target distinct nodes, ERKi
did not synergize with the mechanistically distinct ERKi ulixerti-
nib/BVD-523 (Figure S3C; Table S1J). On the other hand, a sec-
ond pan-RAFi, lifirafenib/BGB-283, also synergized with ERKi
(Figure S3D; Tables S1K and S1L). Similarly, RAFi also syner-
gized with another ERKi, LY3214996 (Figure S3E; Tables S1M
and S1N). Finally, leveraging additional combinations with RAFiation with ERKi (0.08–1.25 mM) (B), MEKi (0.25–4 nM) (C), or EGFRi (0.08–1.25
presentative bliss synergy score heatmap for three independent experiments is
response curves of three independent experiments (with three technical repli-
gy score.
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RAFi, in combination with either erlotinib (EGFRi) or trametinib
(MEKi), also synergistically suppressed growth (Figures 2C and
2D; Tables S1G and S1H). In summary, synergistic cytotoxic
growth suppression was seen only when the combinations
involve inhibitors of distinct nodes of the pathway.
Since a common mechanism for resistance to MEKis involves
reactivation of ERK (Lake et al., 2016; Morrison, 2012; Samatar
and Poulikakos, 2014), we speculated that the RAFi/ERKi com-
bination is more effective than the RAFi/MEKi combination, in
part due to resistance to ERK reactivation. To address this pos-
sibility, we applied MIB/MS (multiplexed kinase inhibitor beads
and mass spectrometry) kinome profiling, a kinome-wide unbi-
ased method that has been used to monitor drug-induced
compensatory signaling activities (Duncan et al., 2012). The ki-
nase activity/expression changes caused by 72-h RAFi/ERKi or
RAFi/MEKi showed near-identical profiles (Figures S3F and
S3G). However, RAFi/ERKi but not RAFi/MEKi showed strong
suppression of ERK1/2 activities. Immunoblot analyses also
showed that the RAFi/ERKi combination caused greater sup-
pression of ERK signaling and phosphorylation of the ERK sub-
strate RSK (Figure S3H). Thus, the RAFi/MEKi combination
showed greater resistance to ERK reactivation.
RAFi/ERKi Treatment Suppresses ERK Signaling
Despite Loss of Negative Feedback Inhibition
Immunoblot analyses of six PDAC cell lines verified that RAFi/
ERKi synergistically reduced pERK levels (Figures 3C, S5C,
and S5D) and that RAFi similarly synergized with the chemically
distinct ERK1/2-selective inhibitor, LY3214996 (Figure S5E). To
identify changes in signaling pathways and the resulting alter-
ations in gene transcription that were quantitatively or qualita-
tively different upon combination treatment versus each inhibitor
alone, we performed reverse phase protein array (RPPA) (Baldelli
et al., 2017) pathway activation mapping (Figure 3A) and RNA
sequencing (RNA-seq) analyses (Figure 3B). Together, these da-
tasets show how RAFi/ERKi disrupted multiple signaling net-
works that in turn disrupted multiple transcription factor-driven
transcriptomes (Figure S4).
RPPA-based pathway mapping revealed dynamic changes in
protein phosphorylation and total protein components of
signaling networks (Figure 3A; Tables S2A and S2B). These
changes were much more robust upon concurrent treatment
with RAFi/ERKi compared to the limited time-dependent alter-
ations caused by either inhibitor alone. The combination sup-
pressed ERK signaling (pRSK, MYC) more strongly than did sin-
gle agents (Figure 3A). Additionally, RAFi/ERKi treatment
strongly reduced SRC family kinase (SFK) phosphorylation and
activation. SFK phosphorylation of ARAF and CRAF is a criticalFigure 3. Concurrent RAF and ERKi Inhibition Disrupts ERK-Dependen
(A) RPPA analyses of PDAC cell lines treated with vehicle control, RAFi (0.3 mM), E
h). RAFi/ERKi-treated PDAC cells were normalized to their respective vehicle co
time point are plotted as fold changes. Red, increased fold change; blue, decrea
(B) GSEA of the cell lines shown in (A). Enriched or depleted gene sets treated wit
(24 h).
(C) Pa16C cells were treated with vehicle control, RAFi (0.3 mM) and ERKi (0.0
determine levels of pERK, total ERK, total MYC, and vinculin. Data are represenRAS-mediated step in the activation of RAF kinase activity (Mor-
rison, 2012). Decision tree analysis confirmed the significant al-
terations of these proteins (Table S2C). Finally, consistent with
the growth inhibitory consequences, the RAFi/ERKi combination
also reduced phosphorylation and activation of mitotic kinases
Aurora and PLK1 (Figure 3A).
We applied MIB/MS and confirmed that 3-day treatment with
RAFi/ERKi caused additive or synergistic alterations in kinase
activity and/or expression compared to RAFi or ERKi alone (Fig-
ure S6A). While RAFi alone reduced activity/expression of BRAF
but not ERK1 or ERK2, and ERKi alone reduced ERK1 and ERK2
but not BRAF, the combination reduced both BRAF and ERK.
Consistent with our previous observation that loss of MYC pro-
tein correlated with ERKi sensitivity, RPPA andMIB/MS revealed
that the combination much more effectively reduced MYC pro-
tein levels (Figures 3A and S5C–S5E). Finally, MIB/MS also indi-
cated that the combination reduced the activity/expression of
Aurora and PLK1 (Figure S6A).
To compare the resulting gene transcription changes induced
by RAFi/ERKi or each agent alone, we performed RNA-seq ana-
lyses after 4 or 24 h of treatment (Figure 3B). The strongest in-
duction of gene transcription was of the interferon (IFN)-a/g-
related gene sets (Figure 3B; Tables S2D–S2I). This is consistent
with a study of Kras-driven colon cancer, where Kras strongly
downregulated IFN-a/g gene sets, suppressing a T cell immune
response (Liao et al., 2019). Consistent with the major role of the
ERK MAPK effector pathway in driving KRAS-regulated gene
expression, gene set enrichment analysis (GSEA) revealed that
RAFi/ERKi suppressed genes upregulated by KRAS and
increased expression of genes downregulated by KRAS (Figures
3B, S5A, and S5B). In particular, RAFi/ERKi strongly suppressed
MYC transcription (Figure S6B) as well as potently silenced the
expression of MYC-regulated genes (Figures 3B and S6C).
RAFi/ERKi also robustly suppressed the expression of a second
oncogenic transcription factor, FOSL1. Both MYC and FOSL1
are well-validated drivers of KRAS-dependent PDAC growth
(Vallejo et al., 2017; Vaseva et al., 2018).
Previous studies showed that single-agent inhibition of any
node of the RAF-MEK-ERK cascade is limited by the loss of
negative feedback on the pathway, causing ERK reactivation
(Lake et al., 2016; Morrison, 2012; Samatar and Poulikakos,
2014). Given its potent suppression of ERK signaling, RAFi/
ERKi also robustly decreased inhibitory feedback on ERK.
RPPA pathway mapping demonstrated that RAFi/ERKi
increased phosphorylation at PAK phosphorylation sites on
ARAF and CRAF that enhance RAF kinase activity (King et al.,
1998) (Figure 3A). PAK signaling drives resistance to combined
BRAF and MEK inhibition in BRAFmutant melanoma by causing
ERK reactivation (Lu et al., 2017). Similarly, there was strongt Signaling and Cellular Processes
RKi (0.04 mM), or the combination for multiple time points (0.25, 1, 8, 24 and 72
ntrol. Proteins with significant phosphorylation or expression changes at 72-h
sed fold change; white, no change.
h RAFi/ERKi compared to RAFi (upper graph) or ERKi (below graph) are shown
4 mM) alone, or the combination (120 h). Cell lysates were immunoblotted to
tative of three independent experiments.
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ERK signaling. These include proteins that directly dephos-
phorylate ERK (e.g., DUSP4–7) as well as proteins that inhibit
RTK activation of RAS via its exchange factor SOS1 or that
inactivate RAS via its negative regulator NF1 (e.g., SPRY2/4,
SPRED1/2, respectively) (Figure S6B). To determine how
RAFi/ERKi treatment was able to retain strong suppression of
ERK signaling despite the extensive loss of negative feedback
on ERK, we examined SHP2, essential for RTK activation of
RAS and ERK (Ahmed et al., 2019). RAFi/ERKi treatment
reduced SHP2 phosphorylation (Figure 3A) and suppressed
transcription of the gene encoding SHP2 (PTPN11) (Figure S6D).
RAFi/ERKi treatment also reduced phosphorylation of the
SHP2 docking site on FRSa (Y436), an adaptor protein that
links the fibroblast growth factor receptor (FGFR) RTK to
SOS1 and RAS activation. FRSa is phosphorylated and inacti-
vated by ERK feedback inhibition (Lax et al., 2002). Thus,
downregulation of SHP2 contributes to the effectiveness of
the RAFi/ERKi combination by creating insensitivity to the
loss of ERK negative feedback.
RAFi/ERKi Treatment Decreases Cell Cycle
Progression, Suppresses Protein Translation Signaling,
and Increases Apoptosis
Pathway mapping at the levels of transcriptional control (RNA-
seq), protein abundance (WB, RPPA, MIB/MS), and protein ac-
tivity (RPPA, MIB/MS) all showed that the biological conse-
quences of RAFi/ERKi treatment are due to multiple distinct
mechanisms (Figure S4). RAFi/ERKi resulted in numerous
changes that decreased the ERK-dependent events that facili-
tate G1 progression, including increased phosphorylation of
p27KIP1, decreased expression of CCND1 (encoding cyclin D1)
(Figure S6B), decreased phosphorylation of the RB tumor sup-
pressor (Figure 3A), loss of E2F1 gene transcription (Figure S6D),
and decreased transcription of E2F target genes (Figure S6E).
RAFi/ERKi suppressed the genes normally upregulated during
G2/M checkpoint progression more strongly than did either
RAFi or ERKi alone (Figure S6E), and they suppressed the activ-
ities/expression of mitotic kinases that are critical regulators of
the G2 to M transition (Figures 3A and S6E). Reflecting these ac-
tivities was a time-dependent decrease in the proliferation
marker Ki67 (Figure 3A).Figure 4. Concurrent RAF and ERK Inhibition Causes Apoptosis
(A) (left) Fold changes (log2) of RNA expression of pro-apoptosis and pro-surviva
lines treated with RAFi/ERKi (0.3 mM and 0.04 mM, respectively) and compared to
are in comparison to the vehicle control for individual graph; p values are from W
(0.3363), BIK (0.2635), HRK (**, 0.003), BCL2L11 (****, 1.49E5), PUMA/BBC3 (*, 0
CASP6 (0.5876), CASP7 (0.5114), CASP8 (0.9215), CASP9 (0.2887), BCL2 (***, 0.
(log2) of the transcripts of the cells treated with RAFi/ERKi (0.3 mM and 0.04 mM,
standard error. All p values shown are in comparison to the vehicle control for indiv
(***, 0.0003),BAK1 (0.4834),BAD (0.6736),BID (0.1958),BIK (0.2171),HRK (***, 0.00
(*, 0.0250), CASP3 (0.7561), CASP4 (*, 0.0229), CASP6 (*, 0.0615), CASP7 (0.159
MCL1 (0.7493), BCL2L2 (0.9250).
(B) Pa01C, Pa02C, or Pa14C cells were treated with vehicle, RAFi (0.3 mM), ER
determine levels of the indicated proteins.
(C) Percent apoptosis of Pa02C and Pa16C cells treated with the vehicle control,
bars are shown as ± SEM.
(D) Representative images of percent apoptosis of the cell lines in (C). FluorescePathway activation mapping also indicated that RAFi/ERKi
synergistically suppressed mTORC1 signaling—which pro-
motes protein translation, as indicated by reduced phosphoryla-
tion of mTORC1 substrates 4EBP1 and S6K—and of the S6K
substrate ribosomal protein S6 (Figure 3A). Strong suppression
of mTORC1-stimulated gene expression was also seen with
RAFi/ERKi (Figures 3B and S7F).
Further, RAFi/ERKi suppressed essentially all genes in the
glycolytic pathway (Figure S6E), consistent with studies demon-
strating that mutant KRAS drives increased transcription of
glycolytic genes through ERK and MYC (Bryant et al., 2019;
Ying et al., 2012). RAFi/ERKi also strongly suppressed genes
involved in mitochondrial biogenesis, mitophagy, and impaired
mitochondrial function (Figure S6E). Thus, RAFi/ERKi-mediated
growth suppression involves the suppression of key metabolic
processes.
Finally, pathway activation mapping also identified increases
in markers of apoptosis caused by RAFi/ERKi; increased
cleaved caspases 3, 6, and 7 and PARP; and increased expres-
sion of the pro-apoptotic proteins BIM and BAD (Figure 3A).
RAFi/ERKi also more strongly increased the transcription of
genes encoding pro-apoptotic proteins (e.g., HRK, BCL2L11
[encoding BIM], PUMA, CASP1) and reduced the transcription
of genes encoding pro-survival proteins (BCL2L1 [encoding
BCLXL], MCL1) than either single agent (Figures 4A, S7A, and
S7B). RAFi/ERKi-treatment-mediated increases in BIM and
BAD were further verified by immunoblotting (Figure 4B). Induc-
tion of apoptosis was verified by flow cytometry analysis.
Whereas RAFi or ERKi treatment alone did not significantly in-
crease apoptosis over vehicle control (<10%), the percentage
of apoptotic cells was more than tripled with RAFi/ERKi (Figures
4C, 4D, and S7C–S7E). Thus, RAFi/ERKi treatment impairs pro-
cesses that promote cell proliferation and enhances processes
that lead to cell death.
Combination RAFi/ERKi Treatment Stimulates
Mesenchymal-to-Epithelial Transition
We noted from the RPPA analyses that combined RAFi/ERKi
treatment increased E-cadherin protein levels (Figures 3A and
S8A), suggesting induction of the mesenchymal-to-epithelial
transition (MET) program. RAFi/ERKi treatment substantially
increased E-cadherin expression (2.4- to 7.3-fold) in four of sixl genes as the averaged values of MIA PaCa-2, Pa02C, Pa14C, and Pa16C cell
RAFi (0.3 mM) (24 h). Error bars are shown as standard error. All p values shown
ald test. Adjusted p values: BAX (0.2971), BAK1 (0.7226), BAD (*, 0.0332), BID
.0221), CASP1 (0.3642), CASP2 (**, 0.0034), CASP3 (0.6314), CASP4 (0.1526),
0014), BCL2L1 (0.1569),MCL1 (0.9338), BCL2L2 (0.9080). (Right) fold changes
respectively) and compared to ERKi (0.04 mM) (24 h). Error bars are shown as
idual graph; p values are determined from theWald test. Adjusted p values:BAX
11),BCL2L11 (****, 7.12E6),PUMA/BBC3 (*, 0.0148),CASP1 (0.3406),CASP2
9), CASP8 (0.4119), CASP9 (0.2582), BCL2 (****, 0.0001), BCL2L1 (**, 0.0032),
Ki (0.04 mM), or the combination (72 h). Cell lysates were immunoblotted to
RAFi (0.3 or 0.6 mM), ERKi (0.04 or 0.08 mM), or the combinations (120 h). Error
nce-activated cell sorting (FACS) analysis was used to measure apoptosis.
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OPEN ACCESScell lines evaluated (Figures 5A, 5B, S8A, and S8B; Tables S3A
and S3B), whereas RAFi or ERKi treatment alone did so to a
lesser degree (Figure 5B). RAFi/MEKi or MEKi/ERKi treatment
also increased E-cadherin expression. In contrast, BRAFi in
combination with either ERKi or MEKi did not significantly in-
crease E-cadherin expression. The limited change in vimentin
transcription and protein levels upon RAFi/ERKi treatment (Fig-
ures 3B, 5A, 5B, and S8B) is consistent with a partial MET
program.
The degree of E-cadherin increase correlated with the degree
of pERK reduction, which was caused most effectively by com-
bination RAFi/ERKi compared to treatment with any single inhib-
itor or other combinations. Increases in E-cadherin also corre-
lated with induction of apoptosis (Figures 4B–4D and S7C–
S7E). In the lines in which E-cadherin was upregulated, RAFi/
ERKi also synergistically induced apoptosis. In contrast, in
Pa01C cells, RAFi/ERKi did not alter E-cadherin levels (Fig-
ure S8B) and caused only a weak induction of apoptosis (Figures
4B and S7C–S7E). Finally, immunofluorescence analyses deter-
mined that RAFi but not ERKi treatment alone enhanced E-cad-
herin staining at cell peripheries and at cell-cell junctions, and
combined RAFi/ERKi treatment caused the strongest upregula-
tion of E-cadherin (Figures 5C and S8C).
We used RNA-seq and GSEA to identify the mechanistic un-
derpinnings of MET induced by RAFi/ERKi. Expression of
CDH1, which encodes E-cadherin, was increased by the combi-
nation (Figure 5D), consistent with reduced levels of several tran-
scription factors that suppress CDH1 transcription (SNAI1,
SNAI2, and ZEB1) (Derynck and Weinberg, 2019) (Figure 5D).
Conversely, RPPA analyses showed that TGFb/SMAD2, a well-
established signaling pathway that drives EMT (epithelial-
mesenchymal transition), was also reduced by RAFi/ERKi (Fig-
ure 3A). RAFi/ERKi caused a significant reduction in PLK1 activ-
ity (Figures S6A and 3A), a driver of EMT through ERK and FRA1
(Wu et al., 2016), with FRA1 also significantly reduced transcrip-
tionally (FOSL1) by this combination (Figure S6B). Thus, induc-
tion of MET-like reprogramming, synergistically induced by
RAFi/ERKi treatment, correlated with induction of apoptosis.
Concurrent Inhibition of Compensatory Signaling
Enhances RAFi/ERKi Cytotoxicity
We next addressed two additional potential improvements in
response to the combination. First, we determined if sequential
treatment could be more effective than concurrent treatment.
We compared low-dose sequential inhibitor treatment to low-
dose concurrent treatment. For sequential treatment, cells
were treated with the initial RAFi or ERKi for 3 days, and thenFigure 5. Concurrent RAF and ERK Inhibition Induces Mesenchymal-t
(A) Pa02C and Pa16C cells were treated with RAFi (0.3 mM), BRAFi (1 mM), MEK
lysates were immunoblotted to determine the levels of the indicated proteins.
(B) Expression levels of the proteins in (A) are plotted as fold changes. All the prote
bars are shown as ± SEM.
(C) Representative immunofluorescence images of Pa02C cells treated with veh
expression and distribution (72 h). Scale bar, 20 mm.
(D) Fold changes in RNAexpression of epithelial andmesenchymalmarkers are plo
Error bars are shown as standard error. p values shown are from Wald test and
CLDN1 (0.8818), TJP1 (0.7301), VIM (0.8465), CDH2 (0.3881), CTNNB1 (0.2445),the other inhibitor ([RAFi + ERKi] or [ERKi + RAFi]) was added.
In Pa02C cells, RAFi/ERKi resulted in 70% fewer cells than
vehicle or either inhibitor alone (Figure 6A). In contrast, sequen-
tial treatment in either order caused a much more limited
decrease (20%–25%). In Pa14C cells, whereas treatment
with either RAFi or ERKi alone caused a 25% decrease, con-
current RAFi/ERKi treatment caused a near-complete suppres-
sion of proliferation (95%). By comparison, RAFi followed by
ERKi, or ERKi followed by RAFi, caused a 75% or 50%
reduction, respectively. Thus, concurrent treatment was more
effective than sequential inhibitor treatment.
Second, we determined if further concurrent inhibition of addi-
tional feedback mechanisms can further enhance RAFi/ERKi
treatment in Pa02C cells, where therewas room for improvement
over the RAFi/ERKi combination (Figure 6A). We observed that
RAFi/ERKi was associated with increased PAK activity. For
example, RPPA demonstrated increased phosphorylation at
the PAK phosphorylation site in CRAF (S338) (King et al., 1998)
(Figures 3A andS4), and thiswas verifiedby immunoblotting (Fig-
ure 6B). Increased LIMK phosphorylation and activation, sup-
ported by increased phosphorylation at S3 of the actin-severing
LIMK substrate Cofilin (Figures 3A and 6B), was also consistent
with upregulation of PAK activity. S3 phosphorylation inactivates
Cofilin, stimulating actin polymerization (Kanellos and Frame,
2016), which is also consistentwith theMET-associated changes
(Derynck and Weinberg, 2019) that we observed. Immunofluo-
rescence images revealed F-actin rearrangement upon RAFi
and/or ERKi treatment (Figure S8C). Thus, RAFi/ERKi was asso-
ciated with increased PAK activation, likely through upregulation
of RTK signaling (Rane and Minden, 2019). Therefore, we deter-
mined if adding the PAK inhibitor (PAKi) FRAX597 would further
enhance RAFi/ERKi growth inhibition. PAKi treatment alone
reduced pCRAF without affecting proliferation. However, the tri-
ple combination ofRAFi/ERKi/PAKiwasable tonearly ablate pro-
liferation (Figures 6A and S9A–S9C).
Another potential compensatory activity is PI3K-AKT activa-
tion, which has been described in response to MEKi treatment.
This also explains how concurrent PI3Ki can enhance ERK
MAPK inhibitory activity (Figure 2A). Accordingly, RAFi/ERKi
treatment of Pa02C cells increased AKT pS473, which was
blocked by the AKT inhibitor (AKTi) MK2206 (Figure 6B). Like
PAKi, AKTi alone did not affect proliferation, but concurrent or
sequential AKTi treatment caused more growth suppression
than RAFi/ERKi treatment alone (Figures 6A and S9A–S9C).
Thus, as with PAKi, the concurrent AKTi treatment blocked a
compensatory activation mechanism and further enhanced
RAFi/ERKi growth suppression.o-Epithelial Transition
i (0.5 nM), or ERKi (0.04 mM) alone or in combination as indicated (120 h). Cell
ins are normalized to loading control and their respective vehicle control. Error
icle, RAFi (0.3 mM), ERKi (0.04 mM), or the combination to visualize E-cadherin
tted for themean average ofMIA PaCa-2, Pa02C, Pa14C, and Pa16C cell lines.
are in comparison to the vehicle control. Adjusted p values: CDH1 (*, 0.0252),
SNAI1 (0.2542), SNAI2 (0.5672), ZEB1 (*, 0.0262).
Cell Reports 31, 107764, June 16, 2020 11
Figure 6. Concurrent Inhibition of Compensatory Signaling Enhances RAFi/ERKi Growth Inhibition
(A) Pa02C and Pa14C cells were treated with RAFi (0.3 mM), ERKi (0.04 mM), FRAX597 (PAKi, 1 mM), or MK2206 (AKTi, 0.6 mM) alone or in combination (slash
indicates concurrent inhibition; plus sign indicates sequential inhibition, inhibitor addition after 72 h). Remaining cells were stained with crystal violet after a total of
5 days. Data are the mean average of two independent experiments. Error bars are shown as ± SEM.
(B) Pa02C and Pa14C cells were treated as in (A) for a total of 5 days. Cell lysates were immunoblotted to determine the levels of the indicated proteins. Data are
representative of two independent experiments.
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OPEN ACCESSLow-Dose RAFi/ERKi Vertical Inhibition Is Effective in
KRAS Mutant Organoids and Tumor-Bearing Rats
We next evaluated the activity of the RAFi/ERKi combination
in other KRAS mutant cancer cell lines and in PDAC organo-
ids and tumor-bearing animals. RAFi/ERKi also caused syner-
gistic growth suppression in KRAS mutant colon and lung12 Cell Reports 31, 107764, June 16, 2020cancer cell lines (Figures 7A and S10A). Extending these an-
alyses to models that may better reflect patient tumor
response, we observed strong synergistic growth inhibition
due to the RAFi/ERKi combination in patient-derived KRAS
mutant PDAC and CRC organoid models (Figures 7B, 7C,
S10B, and S10C).
(legend on next page)
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OPEN ACCESSFinally, we extended the analyses of the RAFi/ERKi combina-
tion to evaluate anti-tumor activity. Since RAFi has poor pharma-
cokinetics in mice, our analyses were limited to analyses of
PDAC-cell-line-induced tumors in immune-compromised rats.
For these analyses, we utilized three PDAC lines that showed
different degrees of response to vertical inhibition combinations.
HPAF-II cells exhibit strong synergistic growth suppression with
RAFi in combination with ERKi, MEKi, and EGFRi (Figures S10E–
S10G; Tables S1D and S1F–S1H). CFPAC1 cells were also
responsive to vertical inhibition combinations, but to a lesser de-
gree, and SW1990 cells showed very limited increased growth
suppression with the combinations.
Whereas ERKi and RAFi alone simply reduced the rate of tu-
mor growth in HPAF-II PDAC xenografts, the RAFi/ERKi vertical
inhibition combination was able to induce tumor regression even
at low doses and did so without statistically significant toxicity
(Figure 7D). The target-based mechanism of tumor regression
is supported by immunoblot analyses of remaining tumor tissue
isolated 4 h after the last treatment (day 21), where the combina-
tion reduced ERK signaling more potently than did either inhibi-
tor alone (Figures 7E and S10D). Analyses of CFPAC-1 also
determined that RAFi/ERKi showed greater activity than each in-
hibitor alone (Figures S10H and S10I). In contrast, RAFi alone did
not significantly reduce SW1990 tumor growth, whereas ERKi
alone or in combination with RAFi shows comparable limited tu-
mor reduction (Figure S10J). No significant toxicity was
observed for both models, as indicated by maintained body
weight (Figures S10H and S10J). Thus, the in vivo responses
closely mirrored the different sensitivities of each cell line when
evaluated in cell culture.
DISCUSSION
Despite the essential role of the RAF-MEK-ERK cascade in
KRAS-dependent PDAC growth, single-agent pharmacologic in-
hibition of this cascade has been ineffective due to the loss of
ERK-dependent negative feedback inhibitory mechanisms that
then cause ERK reactivation and drug resistance in cancer cells.
Normal tissue toxicity has also been a limitation. To address
these limitations, we applied a chemical screen to identify com-
binations that enhance the apoptotic activity of RAFi-MEKi-ER-
Kis. While we identified multiple mechanistically distinct
apoptotic combinations, surprisingly, the most potent combina-
tion was the concurrent inhibition of two distinct nodes of the
three-tiered ERK MAPK cascade, where treatment with a pan-Figure 7. Vertical ERK MAPK Inhibition is Effective in Organoid and Ra
(A) KRASmutant cancer cell lines were treated with RAFi (0.01–2.5 mM) and ERKi (
Calcein AM cell viability assay. Representative bliss synergy score heatmaps for th
white, no effect. The averaged dose response curves of three independent exp
synergy score.
(B)KRASmutant PDAC (10 days) and CRC organoids (5 days) were treatedwith RA
was measured by CellTiter-Glo 3D cell viability assay. Dose response curves and
(C) Representative images of PDAC organoid hM1A treatedwith the vehicle contro
bar, 200 mm. Representative images of CRC organoid OT238 treated with DMSO
100 mm.
(D) Relative tumor volume of theNIH nude rats with implantedHPAF-II cells were tr
(LY ERKi, 10 mpk, QD) for 36 days (left). Body weight changes are shown (right).
(E) Quantitation of blot analysis to determine levels of pRSK of tumor lysates (n =
14 Cell Reports 31, 107764, June 16, 2020RAFi together with an ERK-selective inhibitor (RAFi/ERKi) ex-
hibited the strongest synergistic activity.
Despite strong induction of compensatory signaling activities
that can drive ERK reactivation, the RAFi/ERKi combination
was able to cause synergistic suppression of ERK activation
and system-wide disruption of ERK-dependent cellular
processes, causing cell cycle arrest and apoptosis; loss of
MYC-, E2F- and FRA1-dependent transcriptomes; impaired
metabolism; and induction of MET. That the synergistic
apoptotic growth suppression was strongest at lower inhibitor
concentrations suggests that combined vertical inhibition of
the ERK MAPK signaling circuitry can overcome the limitations
seen with single-agent inhibition and lead to tumor regression
rather than stasis at doses that can reduce normal tissue
toxicity.
The concept of vertical inhibition of ERK MAPK was first
demonstrated in BRAF mutant melanoma, where BRAFi/MEKi
combinations are now approved. This combination strategy de-
lays onset of resistance and reduces toxicity compared with
BRAFi treatment alone, albeit without any reduction in the dosing
compared with BRAFi treatment alone (Dummer et al., 2018;
Flaherty et al., 2012; Larkin et al., 2014; Long et al., 2014). Ex-
tending this concept further, it was shown that a triple RAFi/
MEKi/ERKi combination, with each used in the combination at
the maximum tolerated dose, further delayed the onset of resis-
tance, exhibited stronger suppression of BRAF mutant tumors,
and further reduced toxicity compared with the double-combi-
nation MEKi/ERKi (Xue et al., 2017).
Similar to our RAFi/ERKi vertical inhibition strategy, two
recent studies showed that concurrent RAFi/MEKi treatment
blocked ERK reactivation caused by MEKi treatment alone in
KRAS mutant or WT cancer cell lines (Lamba et al., 2014;
Yen et al., 2018). A third study showed that concurrent MEKi/
ERKi treatment exhibited stronger inhibition of ERK and
increased anti-tumor activity than either inhibitor alone (Mer-
chant et al., 2017). While our study found that combined inhibi-
tion of any two distinct nodes of the EGFR-RAF-MEK-ERK
cascade is superior to any single-node treatment, our analyses
support the RAFi/ERKi combination as the optimal combina-
tion. MEKis and ERKis are limited by CRAF reactivation,
whereas RAFis and MEKis are limited by ERK reactivation;
therefore, the RAFi/ERKi combination targets the two key reac-
tivation nodes. We also determined that concurrent rather than
sequential inhibitor treatment allowed more effective ERK inhi-
bition and growth suppression. Finally, we demonstrated thatt Models of KRAS Mutant Cancers
0.08–1.25 mM) alone or in combination for 120 h. Proliferation wasmeasured by
ree independent experiments is shown (left). Red, synergy; green, antagonism;
eriments are shown (right). Error bars are ± SEM. Synergyavg = average bliss
Fi (0.01–2.5 mM) and ERKi (0.04–0.63 mM) alone or in combination. Proliferation
bliss synergy scores were calculated and represented as in (A).
l DMSO or RAFi (0.16 mM) or ERKi (0.04 mM) alone or in combination (left). Scale
or RAFi (0.31 mM) or ERKi (0.04 mM) alone or in combination (right). Scale bar,
eatedwith RAFi (20mpk, BID) alone or in combination with the ERKi LY3214996
Error bars are shown as ± SEM.
5 animals per group). Error bars are shown as ± SEM.
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compensatory mechanisms (PAK or AKT activation) further
enhance RAFi/ERKi activity.
To address a mechanistic basis for the synergistic and
apoptotic growth suppression of the RAFi/ERKi combination,
we applied RPPA and RNA-seq analyses to identify activities
seen with RAFi/ERKi but not with each inhibitor alone. Together,
these analyses identified a spectrum of ERK-dependent
signaling activities and cellular processes driven more potently
by RAFi/ERKi than RAFi or ERKi alone, where any one perturba-
tion alone would be expected to significantly impair cancer cell
proliferation. Perhaps most significant is the synergistic loss of
a key ERK substrate, MYC, and the suppression of MYC-regu-
lated gene transcription. We showed recently that the loss of
MYC is a key basis for ERKi sensitivity in PDAC and that MYC
suppression alone impairs PDAC tumorigenic growth (Hayes
et al., 2016; Vaseva et al., 2018).
RAFi/ERKi induced more robust suppression of ERK
signaling than was achievable even by high-dose treatment
with each inhibitor alone. Along with this, it also more robustly
induced changes associated with a loss of ERK negative feed-
back mechanisms (Morrison, 2012; Samatar and Poulikakos,
2014), such as suppressing transcription of multiple DUSP fam-
ily genes encoding protein phosphatases that dephosphorylate
and inactivate ERK and activating RTKs that promote PAK-
dependent phosphorylation and activation of CRAF. However,
although these changes would be expected to reactivate ERK
signaling, the combination nevertheless retained the ability to
strongly suppress ERK signaling. Thus, another basis for the
synergistic activity of RAFi/ERKi is insensitivity to the compen-
satory activation mechanisms that limit the effectiveness of RA-
Fis, MEKis, or ERKis when used as single-agent therapies. An
additional unexpected consequence of RAFi/ERKi was inhibi-
tion of SHP2, a key relay mechanism that connects RTK activa-
tion with downstream activation of RAS and ERK signaling.
Recent studies showed that concurrent treatment with a
SHP2 inhibitor can negate the RTK-mediated compensatory
activities that are stimulated by ERK MAPK inhibition and can
synergistically enhance MEKi activity (Ahmed et al., 2019; Fe-
dele et al., 2018; Mainardi et al., 2018; Ruess et al., 2018;
Wong et al., 2018).
Concurrent RAFi/MEKi treatment also caused apoptotic cell
death not seen with each inhibitor alone. A mechanistic basis
for this was identified, where the combination showed stronger
promotion of pro-apoptotic and suppression of pro-survival ac-
tivities. Similarly, RAFi/ERKi synergistically caused G1 arrest
through RB activation of loss of transcription of E2F-mediated
gene expression. Together, these activities provide a basis for
the ability of RAFi/ERKi to suppress PDAC growth at lower con-
centrations of each inhibitor. Thus, vertical inhibition of the ERK
MAPK cascade may reduce the normal tissue toxicity seen with
single-agent therapy and promote cytotoxic rather than cyto-
static inhibition of cancer cell proliferation.
We also observed that RAFi/ERKi induced a partial MET pro-
gram by transcriptional suppression of SNAI1/2 and ZEB1, the
latter of which encodes a transcription factor suppressor of
CDH1 transcription (Derynck and Weinberg, 2019). With
enhanced CDH1 expression promoting enhanced E-cadherinexpression, a key driver of MET, RAFi/ERKi-treated PDAC cells
exhibit a transition from a mesenchymal to an epithelial state.
Further, we observed a trend in which MET was the strongest
in the PDAC cell lines where RAFi/ERKi caused the strongest
induction of apoptosis. This relationship mirrors the earlier find-
ings, where KRAS mutant cancer cell lines with a mesen-
chymal phenotype were those that escaped KRAS addiction,
whereas KRAS mutant cell lines with an epithelial phenotype
were susceptible to KRAS suppression-induced apoptosis
(Singh et al., 2009). Similarly, McCormick and colleagues found
that KRAS mutant cancer cells with an epithelial but not a
mesenchymal phenotype exhibited ERK dependency (Yuan
et al., 2018).
Our determination that the RAFi/ERKi combination caused
both G1 arrest and apoptosis in cancer cells shows the ability
of this combination to block tumorigenic growth and cause tu-
mor regression. Additionally, we found that RAFi/ERKi may
enhance an anti-tumor immune response. Whereas EPHA2 has
been shown to suppress anti-tumor T cell immunity (Markosyan
et al., 2019), kinome profiling upon RAFi/ERKi treatment re-
vealed a reduction of EPHA2 expression/activity. Further, one
of the strongest consequences of RAFi/ERKi was stimulation
of IFN-a/g genes, which would also stimulate a T cell immune
response (Liao et al., 2019). Thus, RAFi/ERKi may cause potent
anti-tumor activity both by suppressing tumor cell growth and by
stimulating a host immune response. Our analyses showed that
RAFi/ERKi caused tumor regression in immune-suppressed
rats. We speculate that the RAFi/ERKi combination will elicit
robust tumor regression in syngeneic PDAC mouse models
where there is an intact immune system.
During our studies, a clinical trial evaluating LY3009120 in pa-
tients with advanced or metastatic cancer was terminated early
based on the lack of sufficient clinical efficacy observed
(NCT02014116), emphasizing the need to consider vertical inhi-
bition combination approaches. One ongoing clinical trial is eval-
uating the pan-RAFi LXH254 in combination with either an ERKi
or a MEKi in patients with advanced or metastatic KRAS mutant
lung cancer or NRAS mutant melanoma (NCT02974725). This
study will provide a clinical comparison of a RAFi/ERKi versus
RAFi/MEKi combination.
In summary, while we identified inhibitors of diverse cellular
components that enhanced the anti-tumor activity of a pan-
RAFi, the most potent combination involved vertical inhibition
of the RAF-MEK-ERK cascade that was effective at low doses.
Our evidence shows that RAFi/ERKi, despite stimulating
robust compensatory mechanisms that can drive ERK reacti-
vation, is refractory to these mechanisms and consequently
achieves pathway suppression at a level not achievable with
each inhibitor alone. This concept is further supported by
our triple combinations with inhibitors of PAK- or AKT-depen-
dent compensatory mechanisms. This causes the loss of a
spectrum of ERK-dependent cellular processes driven by
aberrant gene transcription (G1 progression, pro-survival,
EMT) that then promotes cancer cell death and tumor regres-
sion. Finally, since we found that RAFi/ERKi was effective in
KRAS mutant pancreatic, lung, and colorectal cancer cell
lines, this combination may serve as a pan-KRAS mutant can-
cer therapy.Cell Reports 31, 107764, June 16, 2020 15
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Rabbit monoclonal anti-phospho-c-Raf (Ser338) (56A6) Cell Signaling Technology Cat# 9427; RRID:AB_2067317
Rabbit polyclonal anti-phospho-Cofilin (Ser3) Cell Signaling Technology Cat# 3311; RRID:AB_330238
Rabbit polyclonal anti-Cofilin (D3F9) XP Cell Signaling Technology Cat# 5175; RRID:AB_10622000
Rabbit monoclonal anti-phospho-RSK1 p90 (T359 +
S363) antibody [E238]
Abcam Cat# ab32413; RRID:AB_2181172
Anti-RSK1 Eli Lilly and Company Cat# 334G
Mouse monoclonal anti-phospho-p44/42 MAPK (ERK1/2)
(Thr202/Tyr204) (E10)
Cell Signaling Technology Cat# 9106; RRID:AB_331768
Rabbit monoclonal anti-p44/42 MAPK (Erk1/2) (137F5) Cell Signaling Technology Cat# 4695; RRID:AB_390779
Rabbit polyclonal anti-phospho-S6 Ribosomal Protein
(Ser240/244)
Cell Signaling Technology Cat# 2215; RRID:AB_331682
Mouse monoclonal anti-S6 Ribosomal Protein (54D2) Cell Signaling Technology Cat# 2317; RRID:AB_2238583
Mouse monoclonal anti-b-actin Sigma-Aldrich Cat# A5441; RRID:AB_476744
Bacterial and Virus Strains
DH5a Thermo Fisher Cat# 18258012
Biological Samples
HPAF-II KRAS mutant PDAC rat xenograft tumor tissue Provided by Eli Lilly Star methods section of this paper
CFPAC-1 KRAS mutant PDAC rat xenograft tumor tissue Provided by Eli Lilly Star methods section of this paper
SW1990 KRAS mutant PDAC rat xenograft tumor tissue Provided by Eli Lilly Star methods section of this paper
(Continued on next page)
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Chemicals, Peptides, and Recombinant Proteins
BGB-283 (RAF family kinases and EGFR inhibitor) Selleckchem Cat# S7926
BVD-523 (ERK1/2 inhibitor) Provided by Biomed Biomed
Valley Discoveries Valley Discoveries
Erlotinib (EGFR inhibitor) Selleckchem Cat# S7786
FRAX-597 (PAK1/2/3 inhibitor) Selleckchem Cat# S7271
LY3009120 (pan-RAF inhibitor) Provided by Eli Lilly Provided by Eli Lilly
LY3214996 (ERK1/2 inhibitor) Provided by Eli Lilly Provided by Eli Lilly
MK-2206 (AKT1/2/3 inhibitor) Selleckchem Cat# S1078
SCH772984 (ERK1/2 inhibitor) Selleckchem Cat# S7101
Trametinib (MEK1/2 inhibitor) Selleckchem Cat# S2673
Vemurafenib (BRAF inhibitor) Selleckchem Cat# S1267
Critical Commercial Assays
CellTiter-Glo Luminescent Cell Viability Assay Promega Cat# G7570
RealTime-Glo MT Cell Viability Assay Promega Cat# G9711
CellTox Green Cytotoxicity Assay Promega Cat# G8741
TACS Annexin V-FITC in situ apoptosis detection kit Trevigen, Inc. Cat# 4830
Deposited Data
CRISPR This paper Star Methods section of this paper
Drug sensitivity resistance testing (DSRT) This paper Star Methods section of this paper
Reverse phase protein array (RPPA) This paper Star Methods section of this paper
RNA sequencing EMBL-EBI European
Nucleotide Archive (ENA)
database - https://www.ebi.
ac.uk/ena/
PRJEB38063
Multiplexed kinase inhibitor beads and mass
spectrometry (MIB/MS)
This paper Star Methods section of this paper
Experimental Models: Cell Lines
Human: HPAC (pancreatic adenocarcinoma) ATCC Cat# CRL-2119, RRID:CVCL_3517
Human: MIA PaCa-2 (pancreatic ductal adenocarcinoma) ATCC CRM-CRL-1420, RRID:CVCL_0428
Human: PANC-1 (pancreatic ductal adenocarcinoma) ATCC Cat# CRL-1469, RRID:CVCL_0480
Human: Pa01C (pancreatic ductal adenocarcinoma) (Jones et al., 2008) (Jones et al., 2008)
Human: Pa02C (pancreatic ductal adenocarcinoma) (Jones et al., 2008) (Jones et al., 2008)
Human: Pa03C (pancreatic ductal adenocarcinoma) (Jones et al., 2008) (Jones et al., 2008)
Human: Pa04C (pancreatic ductal adenocarcinoma) (Jones et al., 2008) (Jones et al., 2008)
Human: Pa14C (pancreatic ductal adenocarcinoma) (Jones et al., 2008) (Jones et al., 2008)
Human: Pa16C (pancreatic ductal adenocarcinoma) (Jones et al., 2008) (Jones et al., 2008)
Human: A549 (lung adenocarcinoma) ATCC Cat# CCL-185, RRID:CVCL_0023
Human: NCI-H358 (minimally invasive lung
adenocarcinoma)
ATCC Cat# CRL-5807, RRID:CVCL_1559
Human: SW900 (squamous cell lung carcinoma) ATCC ATCC Cat# HTB-59, RRID:CVCL_1731
Human: SW620 (Colon adenocarcinoma) ATCC Cat# CCL-227, RRID:CVCL_0547
Human: HPAF-II (pancreatic adenocarcinoma) ATCC Cat# CRL-1997, RRID:CVCL_0313
Human: CFPAC-1 (pancreatic ductal adenocarcinoma,
cystic fibrosis)
ATCC Cat# CRL-1918, RRID:CVCL_1119
Human: SW1990 (pancreatic adenocarcinoma) ATCC Cat# CRL-2172, RRID:CVCL_1723
Experimental Models: Organisms/Strains
Human: hM1A PDAC organoid (Boj et al., 2015) (Boj et al., 2015)
Human: hT2 PDAC organoid (Boj et al., 2015) (Boj et al., 2015)
(Continued on next page)
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Human: OT227 CRC organoid (Sch€utte et al., 2017) (Sch€utte et al., 2017)
Human: OT228 CRC organoid (Sch€utte et al., 2017) (Sch€utte et al., 2017)
Human: OT302 CRC organoid (Sch€utte et al., 2017) (Sch€utte et al., 2017)
Rat: HPAF II PDAC model ATCC ATCC# CRL-1997
Rat: CFPAC-1 PDAC model ATCC ATCC# CRL-1918
Rat: SW1990 PDAC model ATCC ATCC# CRL-2172
Oligonucleotides
shRNA targeting sequence: ARAF #1
CCGGCCAGCCAATCAATGTTCGTCTCTCG
AGAGACGAACATTGATTGGCTGGTTTTT
(Freeman et al., 2013) TRCN0000000567
shRNA targeting sequence: ARAF #2
CCGGGTAGAGGAGGTAGTGATGGAACTC
GAGTTCCATCACTACCTCCTCTACTTTTT
(Freeman et al., 2013) TRCN0000000568
shRNA targeting sequence: BRAF #1
CCGGCCGCTGTCAAACATGTGGTTACTCG
AGTAACCACATGTTTGACAGCGGTTTTT
(Freeman et al., 2013) TRCN0000006290
shRNA targeting sequence: BRAF #2
CCGGGCTGGTTTCCAAACAGAGGATCTCG
AGATCCTCTGTTTGGAAACCAGCTTTTT
(Freeman et al., 2013) TRCN0000006291
shRNA targeting sequence: CRAF #1
CCGGGCTTCCTTATTCTCACATCAACTC
GAGTTGATGTGAGAATAAGGAAGCTTTTT
(Freeman et al., 2013) TRCN0000001065
shRNA targeting sequence: CRAF #2
CCGGCGGAGATGTTGCAGTAAAGATCTC
GAGATCTTTACTGCAACATCTCCGTTTTT
(Freeman et al., 2013) TRCN0000001066
shRNA targeting sequence: KRAS #1
CAGTTGAGACCTTCTAATTGG
(Singh et al., 2009) TRCN0000010369
Software and Algorithms
ImageJ version 2.0.0-rc-69/1.52n software (Schneider et al., 2012) https://imagej.nih.gov/ij/
DESeq2 package (version 1.22.2) (Love et al., 2014) https://bioconductor.org/packages/
release/bioc/html/DESeq2.html
GSEA (version 3.0) (Subramanian et al., 2005) http://www.gsea-msigdb.org/gsea/index.jsp
MSigDB (version 6.2) (Liberzon et al., 2015) https://www.gsea-msigdb.org/gsea/
msigdb/index.jsp
Prism software (version 8.0.2) GraphPad https://www.graphpad.com/scientific-
software/prism/
Python (version 3.6.3) Python Software Foundation https://www.python.org/
R (version 3.5.1) R Core Team (2013) http://www.R-project.org/
Sci-Kit Learn (version 0.20.3) (Pedregosa et al., 2011) https://scikit-learn.org
SynergyFinder (version 1.6.1) (Ianevski et al., 2017) https://bioconductor.org/packages/
release/bioc/html/synergyfinder.html
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Lead Contact
Requests for further information and reagents should be directed to and will be fulfilled by the Lead Contact, Channing J. Der (cjder@
med.unc.edu).
Materials Availabilty
This study did not generate any new reagents.Cell Reports 31, 107764, June 16, 2020 e3
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The accession number for the binary sequence alignment/map (BAM) files of RNA-seq data of cell lines MIA PaCA-2, Pa02C, Pa14C
and Pa16C reported in this paper is [ENA] (the EMBL-EBI European Nucleotide Archive) PRJEB38063 (https://www.ebi.ac.uk/ena/,
https://www.ebi.ac.uk/ena/data/view/PRJEB38063). The file names containing ‘‘R’’ indicate RAF inhibitor treated samples, ‘‘E’’ indi-
cate ERK inhibitor treated samples, ‘‘C’’ indicate combination treated samples and ‘‘V’’ indicate vehicle control. The file names con-
taining ‘‘4’’ and ‘‘24’’ indicate treatment time of 4 hours and 24 hours respectively.’’
This study did not generate any unique codes.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell culture
The patient-derived xenograft (PDX) human pancreatic cancer cell lines Pa01C, Pa02C, Pa03C, Pa04C, Pa14C and Pa16C were
gifted by Dr. Anirban Maitra (MD Anderson Cancer Center). Conventional human pancreatic cancer cell lines (MIA PaCa-2,
PANC-1, HPAF-II, CFPAC-1 and SW 1990), lung cancer cell lines (A549, NCI-H358 and SW900) and colorectal cancer cell line
(SW620) were obtained from American Type Culture Collection (ATCC). PDX pancreatic and colorectal cancer cell lines were main-
tained in Dulbecco’s Modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS). HPAF-II, CFPAC-1 and SW
1990 pancreatic cancer cell lines were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS). Lung
cancer cell lines were maintained in RPMI medium supplemented with 10% FBS. Cell lines were tested for mycoplasma. Pancreatic
cancer cell line identities were verified by Short Tandem Repeat (STR) analysis.
Patient-Derived Organoids
The human pancreatic cancer organoids were provided by Dr. David Tuveson (Cold Spring Harbor Laboratory). The patient-derived
PDAC organoids hM1A KRASG12D and hT2 KRASG12R were cultured at 37C in 5%CO2. Cells were seeded in growth factor reduced
Matrigel (Corning) domes and fed with complete human feeding medium: advanced DMEM/F12 based WRN condition media
(L-WRN (ATCC CRL-3276)), 1x B27 supplement, 10 mM HEPES, 0.01 mM GlutaMAX, 10 mM nicotinamide, 1.25 mM N-acetylcys-
teine, 50 ng/mL hEGF, 100 ng/mL hFGF10, 0.01 mM hGastrin I, 500 nM A83-01, 1 mM PGE2 and additionally 10.5 mM Y27632 (Boj
et al., 2015). Organoids were tested for mycoplasma. The patient-derived colorectal organoids OT227 KRASG13D, OT238 KRASG12D
and OT302 KRASG12D were previously fully characterized in terms of genomic alterations by Sch€utte et al. (2017). CRC organoids
were cultured in crypt culture medium (CCM) containing advanced DMEM/F12 (GIBCO) supplemented with 1x GlutaMAX (GIBCO),
10 mM HEPES buffer (GIBCO), Penicillin/Streptomycin (100 U/ml/100 mg/ml), 1 mM N-acetylcysteine (Sigma), 1x N2 Supplement
(GIBCO), 1x B27 Supplement (GIBCO) and prepared with freshly added hFGF basic/FGF2 (20 ng/ml) (Sigma) and hEGF
(50 ng/ml) (Sigma).
Rats
All in vivo studies were performed in accordance with the American Association for Laboratory Animal Care institutional guidelines
and approved by The Eli Lilly and Company Animal Care and Use Committee. HPAF-II, CFPAC-1 and SW1990 pancreatic cancer
cells (ATCC cat#CRL-1997)) were cultured in MEM supplemented with 10% heat inactivated fetal bovine serum, sodium pyruvate,
and nonessential amino acids. Cell lines were tested for mycoplasma and identity was confirmed by STR-based DNA finger printing
and multiplex PCR (IDEXX-Radil). Logarithmically growing cells with < 7 passage from the thaw were used for implantation.
In all three studies (HPAF II, CFPAC1 and SW1990), 7-8 weeks old (120-145 g) female NIH Nude (NIHRNU-IVI) rats from Taconic
Farms Inc were used.
Animal maintenance and care:
12 hr light/dark cycle, Temp: 68-75C, Humidity: 30%–70% relative, 3-5 animals /cage, Bedding: Bed o cob, Filtered water,
Feeding: Ad libitum, Feed: Standard chow
METHOD DETAILS
shRNA and Plasmid Transfections
The shRNAs targeting ARAF (TRCN0000000567, TRCN0000000568), BRAF (TRCN0000006290, TRCN0000006291), and CRAF
(TRCN0000001065, TRCN0000001066) were provided Deborah K. Morrison (NCI), and shRNA targeting KRAS
(TRCN0000010369) was provided by J. Settleman (Genentech). 0.93 106 HEK293T cells were seeded on T25 flasks and incubated
overnight. To generate lentiviral particles, HEK293T cells were transfected with plasmids by using FuGENE6 (Roche) protocol. Vector
(4 mg), pSPAX2 (3 mg) and pMD2.G (1 mg) plasmids were diluted in 400 mL Opti-MEMmedium. Transfection reagent FuGENE6 (24 ml)
was added into the diluted plasmid mixture and incubated for 15 min at room temperature. Transfection mixture was added onto
HEK293T cells dropwise and incubated overnight. Transfection medium was replaced with DMEM with 20% FBS and incubated
for 48 hr. Virus particles were collected. 106 cells were infected by 0.5 mL virus combined with polybrene (final concentration of
8 mg/ml) in 2 mL medium. The medium was replaced with complete medium (DMEM with 10% FBS) after 8 hr. Antibiotic selectione4 Cell Reports 31, 107764, June 16, 2020
Article
ll
OPEN ACCESSwas started after 12-16 hr of incubation in complete medium. Upon 72 or 120 hr of antibiotic selection, cells were collected for immu-
noblotting, anchorage-independent colony formation, or proliferation assays.
To quantify anchorage-independent colony formation, 400-1000 cells per well (depending on the cell line) were seeded on 6-well
plates and incubated for R 10 days at 37C until colonies were formed. Colonies were stained by crystal violet and quantified by
ImageJ (version 2.0.0). Briefly, the 6-well plate images were converted to 8-bit images. The same thresholding was applied to all
the wells to subtract background. The mean intensities were normalized by dividing each value to the average intensity of its respec-
tive control well.
To quantify proliferation, 2x105 cells per well were seeded and incubated overnight at 37C. The next day cells were treated with
LY3009120 (0.3 mM), SCH772984 (0.04 mM), the PAK1 inhibitor FRAX-597 (0.5 mM), or the pan-AKT1/2/3 inhibitor MK-2206 (0.6 mM)
alone or in various combinations as indicated in the figures for a total of 10 days. Cells were stained by crystal violet and quantified by
ImageJ as described above.
Immunoblotting
The human pancreatic cancer cells were washed with ice-cold PBS, lysed with ice-cold 1% RIPA buffer (50 mM Tris-HCl, pH 8.0,
150 mM NaCl, 0.01% SDS, 0.5% sodium deoxycholate, 1% NP-40) supplemented with protease (Roche) and phosphatase (Sigma)
inhibitors, scraped and incubated in cold tubes for 10 min on ice. Cell lysates were centrifuged at 18,213 x g (12,700 rpm) at 4C for
10 min, and the supernatant was used for determining protein concentration by Bradford assay (Bio-Rad). Standard immunoblotting
procedures were followed. Membranes were blocked in 5% BSA diluted in TBST (TBS with 0.05% Tween 20) for 1 hr.
Proliferation Assays
The cancer cells (103 per well) were seeded in 96-well plates, incubated overnight, and treated with small molecule inhibitors. Cells
were treated with a pan-RAF inhibitor LY3009120 (0.01-2.5 mM) alone or in combination with ERK1/2 inhibitor SCH772984 (0.04-
1.25 mM, 72 or 120 hr), ERK1/2 inhibitor LY3214996 (0.04-1.25 mM, 120 hr), MEK1/2 inhibitor trametinib (Mekinist) (0.125-4.0 nM,
120 hr), or EGFR inhibitor erlotinib (Tarceva) (0.01-2.5 mM, 120 hr). Cells were treated with ERK1/2 inhibitor SCH772984 (0.04-
0.16 mM) alone or in combination with mutant BRAF-selective inhibitor vemurafenib (Zelboraf) (0.01-2.5 mM), ERK1/2 inhibitor ulix-
ertinib (BVD-523) (0.01-2.5 mM), or RAF family kinases and EGFR inhibitor BGB-283 (lifirafenib) (0.01-2.5 mM) for 120 hr. Vehicle con-
trol DMSO was kept % 0.01%. Cells were incubated at 37C 72 or 120 hr. Proliferation was measured by counting calcein AM
(500 nM, 20 min) (Invitrogen) labeled live cells by using a SpectraMax i3x multimode detection platform (Molecular Devices). Bliss
synergy scores were calculated using SynergyFinder (version 1.6.1) package of R (version 3.5.1) environment. An R script was
used to convert the 96-well plate format data into SynergyFinder data table format. SynergyFinder data table includes the identifiers
for inhbitiors, row and column numbers, the name of the inhibitors in a dose-response matrix, the concentration and its unit for each
well, and the response, which is % inhibition in cell growth. SynergyFinder calculates a synergy score based on Bliss model (Bliss,
1939).
CRISPR/Cas9 Screen
Design and Cloning of the CRISPR Library
In order to assemble a library of druggable, cancer-relevant genes, we manually curated 2,240 genes from six broad domains of in-
terest: chromatin modifiers (including epigenetic readers, writers, erasers), the full kinome, pathways responsible for mediating and
repairing DNA damage, genes/proteins that represent the target of FDA-approved drugs for any indication, genes that are frequently
mutated in cancer, and genes that comprise the pathways most frequently dysregulated in tumorigenesis, tumor maintenance, and
drug resistance. Beyond these genes of interest, we also selected 150 genes, chosen for their demonstrated dispensability or non-
dispensability across a series of essentiality studies (Hart et al., 2014), to be used as control genes. We selected five constructs to
represent each of these 2,390 genes, producing a subtotal of 11,950 short guide RNA (sgRNA) constructs. Finally, we included 50
non-targeting control constructs for a total of 12,000 sgRNAs. All of the CRISPR constructs used in this library were selected from a
previously characterized and published library (Wang et al., 2014). sgRNA inserts corresponding to the entire 12,000 sgRNA library
were synthesized by CustomArray, Inc in the form:
GGAAAGGACGAAACACCGXXXXXXXXXXXXXXXXXXXXGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGC. Where ‘‘X’’ de-
notes variable 20-mer sgRNA sequence unique to each construct. The resulting library was cloned using previously published
methods (Shalem et al., 2014). In brief, the oligo pool was diluted 1:100 in molecular biology grade water and amplified using
NEB Phusion Hotstart Flex with the following primers and PCR protocol:
Array F: TAACTTGAAAGTATTTCGATTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCG
Array R: ACTTTTTCAAGTTGATAACGGACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAAC
PCR protocol: 98C/30 s, 183 [98C/10 s, 63C/10 s, 72C/15 s], 72C/3 min. Resulting inserts were processed with Axygen PCR
clean-up beads (ratio of 1.8 x starting volume; Fisher Scientific) and reconstituted in half the volume of molecular biology grade water.
In parallel, the lentiCRISPRv2 vector (Addgene ID 52961) was digested with BsmBI (Thermo Fisher) at 37C for 2 hr. The product was
run out for size-selection on a 1% agarose gel and the 13 kB band was gel-extracted. Using 100 ng of BsmBI-cleavedCell Reports 31, 107764, June 16, 2020 e5
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30 min, at 50C). Following Gibson assembly, 1 ml of the product was electroporated into electrocompetent Lucigen 10G-elite cells,
spread onto LB-ampicillin plates and incubated at 37C for 16 hr. The efficiency of transformation was estimated by plating limiting
dilutions on LB-ampicillin plates. Multiple electroporations were performed, producing an estimated 500,000 total colonies, sufficient
to cover the entire library of 12,000 constructsmore than 40-fold. The colonies were collected in LB and plasmid extra was performed
using a plasmid maxiprep kit (QIAGEN). DNA was used to make lentivirus.
CRISPR/Cas9 Library Lentivirus Generation and Infection
Lentivirus generation was performed as described previously (Martz et al., 2014). HEK293T cells were seeded in 15 cm dishes and
grown up to 50% confluency. Library plasmid (6.25 mg), psPAX2 (5.6 mg), pVSVg (0.625 mg) and transfection reagent FuGENE6
(Roche) was incubated for 30 min. The transfection mixture was added to the cells and incubated overnight. Harvest media
(DMEM with 30% FBS) was added the next day and incubated for 48 hr. Virus particles were collected and filtered through a
0.45 mm filter. Virus tittering was performed as described previously (Martz et al., 2014).
Human pancreatic cancer cell lines (5x105 per well) were seeded in 6-well plates and incubated overnight. Next day, virus was
added at an MOI of 0.3. Upon puromycin selection, a day 2 sample is taken to ensure library representation and the remaining cells
were seeded in 500 cm dishes. The cells were maintained in puromycin media for 10 days to achieve 1,000x coverage of the library.
The cells were either treated with vehicle control DMSO (%0.01%) or LY3009120 RAF inhibitor (GI20-30). The cells were collected after
2 and 4 weeks, DNA was extracted with DNeasy Blood & Tissue Kit (QIAGEN) and prepared for sequencing.
Drug Sensitivity Resistance Testing (DSRT) Chemical Library Screen
The DSRT platform that has been described previously (Gautam et al., 2016; Pemovska et al., 2013) was adapted for the PDAC cell
lines. 525 different oncological compounds were utilized in this study (Table S2J). The compounds were plated to white clear bottom
384-well plates (Corning #3712) in 5 concentrations in 10-fold dilution steps, thus covering an individually optimized 10,000-fold con-
centration range for each compound using an Echo 550 Liquid Handler (Labcyte). Cell killing 100 mM benzethonium chloride (BzCl2)
and 0.1% dimethyl sulfoxide (DMSO) vehicle were used as positive and negative controls respectively. For the combination screen-
ings, single concentration of RAFi (LY3009120), MEKi (trametinib), ERKi (SCH772984) in final concentrations of 2 mM, 25 nM, or
100 nM respectively, were added on top of 525 compound 5-concentrations plates using Echo 550. Pa01C, Pa02C, Pa03C,
Pa04C, Pa14C, Pa18C and MDA-PATC53 were screened in combination with ravoxertinib whereas the remaining cell lines were
screened in combination with SCH772984. All subsequent liquid handling was performed using a MultiDrop dispenser (Thermo Sci-
entific). The pre-dispensed compounds were dissolved in 5 mL of culture media, containing viability and cytotoxicity measurement
reagents, RealTime-Glo andCellTox Green (Promega), respectively and left on a plate shaker at room temperature for 30min. Twenty
ml cell suspension containing optimized number of cells per well were seeded in the drugged plates. After 72 hr incubation, the multi-
plexed cell viability (luminescence) and cytotoxicity (fluorescence) was recorded using a PheraStar plate reader (BMG Labtech). The
raw luminescence and fluorescence data were analyzed in Breeze software, an in-house developed data analysis pipeline at Institute
for molecular Medicine Finland (FIMM), to calculate the drug sensitivity scores (DSS) (Yadav et al., 2014). The drug combination se-
lective effect was calculated as combination DSS minus single agent DSS, termed as ‘‘Delta DSS.’’
Reverse Phase Protein Array (RPPA)
Human pancreatic cancer cell linesMIA PaCA-2, Pa02C, Pa14C andPa16Cwere seeded (2x105 cells per well) onto 6-well plates. The
next day cells were treated with vehicle control DMSO (%0.01%), LY3009120 RAFi (0.3 mM), SCH772984 ERKi (0.04 mM), or the com-
bination of the two inhibitors for 15 min, and 1, 8, 24 or 72 hr. Cells were lysed and processed as previously described (Baldelli et al.,
2017). Coomassie Protein Assay Reagent kit (Thermo Fisher Scientific) was used to measure protein concentration, following the
manufacturer’s instructions. 2X Tris-glycine SDS sample buffer (Life Technologies) with 5% b-mercaptoethanol was used to dilute
cell lysates to 0.5 mg/ml. Samples were boiled for 8 min and stored at 20C until arrayed. An Aushon 2470 automated system
(Aushon BioSystems) (Pierobon et al., 2017) was used to immobilize cell lysates and the internal controls and print in technical rep-
licates (n = 3) onto nitrocellulose-coated glass slides (Grace Bio-Labs). Sypro Ruby Protein Blot Stain (Molecular Probes) was used to
quantify protein concentration in each sample, following the manufacturer’s instructions. Reblot Antibody Stripping solution (Chem-
icon) was used to pretreat the remaining arrays (15 min at room temperature). The arrays were washed with PBS and incubated in I-
block (Tropix) for 5 hr before antibody staining (Baldelli et al., 2017). Arrays were incubated with 3% H2O2, Avidin, Biotin (DakoCy-
tomation), and an additional serum-free protein block (DakoCytomation) to reduce nonspecific binding of endogenous proteins.
Staining was performed using an automated system (DakoCytomation) was used. Each slide was probed for 30 min with one anti-
body targeting the protein of interest, with 157 antibodies that target proteins involved in signaling networks that regulate cell growth,
survival and metabolism were used to probe arrays (Table S2J). All antibodies used were validated as described previously (Signore
and Reeder, 2012). Signal amplification was determined by using biotinylated anti-rabbit (Vector Laboratories) or anti-mouse sec-
ondary antibody (DakoCytomation) and a commercially available tyramide-based avidin-biotin amplification system (Catalyzed
Signal Amplification System, DakoCytomation). IRDye 680RD streptavidin (LI-COR Biosciences) fluorescent detection system
was used. TECAN laser scanner was used to scan Sypro Ruby and antibody stained slides, and the images were analyzed using
commercially available software (MicroVigene Version 5.1.0.0, Vigenetech) as previously described (Baldelli et al., 2015).
RNA Sequencing
The human pancreatic cancer cell lines MIA PaCA-2, Pa02C, Pa14C and Pa16C were seeded at50% confluency. The next day the
cells were treated with the vehicle control DMSO (%0.01%), LY3009120 (RAFi, 0.3 mM), SCH772984 (ERKi, 0.04 mM) or thee6 Cell Reports 31, 107764, June 16, 2020
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PBS. The cells were collected by centrifugation at 326 x g (500 rpm) at 4C for 10 min, and the cell pellets were flash frozen by liquid
nitrogen. Whole transcriptome libraries were generated from total RNA (50 ng) of the human pancreatic cancer cell lines by using
Illumina’s Truseq RNA Sample Prep to perform RNA sequencing. Oligo(dT) magnetic beads were used to select Poly(A) mRNA,
and TruSeq PCR Master Mix and primer cocktail were used to enrich the libraries. The Agilent Bioanalyzer and Invitrogen Qubit
were used to clean and quantify the amplified products. The Illumina HiSeq 2500 was used to sequence the clustered flowcell for
paired 100-bp reads by using Illumina’s TruSeq SBS Kit V3. Lane level fastq files were appended together if they were sequenced
across multiple lanes. These fastq files were then aligned with STAR 2.3.1 to GRCh37.62 using ensembl.74.genes.gtf as GTF files.
Transcript abundances were quantified by HTSeq in total read counts per transcript.
MIB/MS
The human pancreatic cancer cell lineMIA PaCA-2 was treated with the vehicle control DMSO (%0.01%), LY3009120 (RAFi; 0.3 mM),
trametinib (MEKi; 0.5 nM), SCH772984 ERKi (0.04 mM), or the combinations of RAFi/MEKi and RAFi/ERKi for 72 hr. The samples were
prepared as described previously (Duncan et al., 2012). Briefly, the cells were processed on ice by using MIB lysis buffer [50 mM
HEPES (pH 7.5), 0.5%Triton X-100, 150mMNaCl, 1mMEDTA, 1mMEGTA, 10mMsodium fluoride, 2.5mM sodium orthovanadate,
1X protease inhibitor cocktail (Roche), 1%phosphatase inhibitor cocktail 2 (Sigma-Aldrich), and 1%of phosphatase inhibitor cocktail
3 (Sigma-Aldrich)]. The cell lysateswere sonicated (33 10 s) on ice andwere collected by centrifugation (10,000 x g) at 4C for 10min.
The supernatant was filtered through a 0.2 mm SFCA membrane. The lysates (5 mg protein per experiment) were gravity-flowed
over multiplexed kinase inhibitor beads (MIBs) (Sepharose conjugated to VI-16832, CTx-0294885, PP58, Purvalanol B,
UNC8088A, UNC21474). MIBs were washed with high (1 M NaCl) and low salt (150 mM NaCl + 0.1% SDS) lysis buffers without
the inhibitors. The samples were boiled with the elution buffer (100 mM Tris-HCl, 0.5% SDS, and 1% b-mercaptoethanol, pH 6.8)
at 100C for 5 min to elute the bound kinases from MIBs. The eluted kinases (proteins) were concentrated with Amicon Ultra-4
(10K cutoff) spin columns (Millipore), purified by removing the detergent using methanol/chloroform extraction, and digested by
sequencing grade Trypsin (Promega) overnight at 37C. Hydrated ethyl acetate extraction was used to remove triton, and PepClean
C-18 spin columns (Pierce, Thermo Scientific) were used to de-salt the digested peptides.
Biological triplicates of the MIB samples were analyzed by LC-MS/MS as described previously (Vaseva et al., 2018). Briefly, each
sample was injected onto an Easy Spray PepMap C18 column (75 mm id 3 25 cm, 2 mm particle size) (Thermo Scientific) and sepa-
rated over a 2 hr method. The gradient for separation consisted of 5%–32%mobile phase B at a 250 nl/min flow rate, where mobile
phase A was 0.1% formic acid in water and mobile phase B consisted of 0.1% formic acid in ACN. The Thermo QExactive HF was
operated in data-dependent mode where the 15 most intense precursors were selected for subsequent HCD fragmentation (set to
27%).
Flow Cytometry
TACS Annexin V-FITC Kit (BD Biosciences) was used to measure apoptosis according to the manufacturer’s instructions. De-
tached cells in the culture medium and the trypsinized cells were collected, mixed and centrifuged at 300 x g for 5 min at room tem-
perature. The cells were washed with ice-cold PBS and incubated in Annexin V Incubation Reagent (1% Annexin V-FITC, 1X propi-
dium iodide solution, in 1X calcium-containing binding buffer) in the dark for 15 min at room temperature. Cell mixture was diluted 1:5
in 1X binding buffer. BD LSRFortessa flow cytometer was used to analyze the cells. FACSDiva v8.0.1 was used to collect and export
30,000 cells to be analyzed with Cytobank. A ‘‘cells‘‘ gate was generated to avoid small and large debris in the bottom right corner or
off-scale on either axis by using a side scatter area (SSC-A) (y) versus forward scatter area (FSC-A) (x) dot plot. Propidium iodide area
(PI-A) (y) versus fluorescein isothiocyanate area (FITC-A) (x) dot plot was used to measure apoptosis. Vehicle control DMSO
(% 0.01%) treated cells were assigned as the healthy cell population by a quadrant gate (PI-A negative, FITC-A negative).
Immunofluorescence
Human pancreatic cancer cells Pa01C and Pa02C were plated on 10 mg/ml fibronectin-coated glass coverslips and treated with
DMSO (%0.01%), LY3009120 RAFi (0.3 mM), SCH772984 ERKi (0.04 mM), or the combination of the two inhibitors for 72 hr. The cells
were washed twice with PBS, fixed in 3.7% formaldehyde (Fisher Scientific) for 10 min at room temperature, washed with PBS and
permeabilized with 0.1% Triton X-100 (Sigma) for 5 min at room temperature. Non-specific signals were blocked using 2% BSA
(Sigma) in PBS for 30 min at room temperature. Cells were incubated with the primary antibody (diluted in 2% BSA-PBS) for
40 min at room temperature, followed by three washes with PBS and incubation with the secondary antibody (diluted in 2% BSA-
PBS) for 45 min at room temperature. After washing three times with PBS, cells were mounted with Prolong Diamond antifade
mounting media (Invitrogen). E-cadherin was visualized by anti-rabbit E-cadherin (clone 24E10; Cell Signaling, 1:100) followed by
a goat-anti-rabbit Alexa Fluor-568 conjugated secondary antibody (Invitrogen, 1:200). Phalloidin conjugated with an Alexa 488 fluo-
rophore (Invitrogen, 1:200) was used to visualize F-actin and DAPI (Invitrogen, 1:10000) was used to label the nucleus. Images were
acquired in five random fields on an Olympus FV1000 confocal microscope using a 40x objective (1.2 zoom) and amaximally opened
pinhole.
Organoid Viability Assay
PDAC organoids were dissociated and 3000 single cells per well were seeded in 150 ml of 10% growth factor reducedMatrigel (Corn-
ing) and 90% human organoid feeding media + 10.5 mM Y27632 (Selleckchem) into Poly(2-hydroxyethyl methacrylate) (SIGMA)
coated 96-well clear flat bottom plates (Corning Ref. 3903). On the second day after seeding organoids were drugged with
SCH772984 (0.04 mM to 0.63 mM) and LY3009120 (0.01 mM to 2.5 mM). Ten days after drugging, organoids were imaged with theCell Reports 31, 107764, June 16, 2020 e7
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CellTiter-Glo 3D Cell Viability Assay (Promega) according to manufactures protocol on the SpectraMax i3x plate reader. Colorectal
organoid cultures were immersed in 90% Matrigel (BD, Cat# 356231), plated onto 24-well plates in 20 ml drops per well and upon
solidification overlaid with 500 ml CCM. For inhibitor experiments the organoids were harvested and trypsinized until single cell sus-
pension was available for plating onto flat bottom 96-well format (Corning, Cat. No. 3603) (outer wells filled with PBS only). Per well
1000-1500 single cell organoids were plated in a 6 ml Matrigel drop and 150 ml CCM was added to culture PD3D’s for two days prior
inhibitor addition. The inhibitors were added to the CRC PD3D’s as specified using the Tecan 300D dispenser and incubated for
5 days prior monitoring of proliferation by microscopy (Exp1-3, Tecan Spark, Exp 4 and 5, Keyence BZ-X710) and CellTiter-Glo
3D measurement.
Bliss synergy scores were calculated using SynergyFinder as described in ‘‘Proliferation assays.’’
PDAC Xenograft Study
Five x 106 HPAF II (ATCC# CRL-1997), CFPAC-1 (ATCC# CRL-1918) or SW1990 (ATCC# CRL-2172) pancreatic cancer cells in a 1:1
Matrigel mix (HPAF-II and SW1990; 0.2 mL total volume) were injected subcutaneously into the right hind flank of 7- to 8-week old
(125-150 g) female athymic NIH (NIHRNU-IVI) nude rats (Taconic Farms). After tumors reached 200-300mm3, animals were random-
ized into groups of six. Both LY3214996/ERKi and LY3009120/RAFi were administered orally (gavage) in 0.2 mL volume of vehicle
(1%HEC/0.25% Tween 80/0.05% Antifoam) for 21 days. Tumor volume and body weight are measured twice weekly. Tumor volume
is estimated by using the formula: v = l x w23 0.536where l = larger of measured diameter andw = smaller of perpendicular diameter.
QUANTIFICATION AND STATISTICAL ANALYSIS
Prism Software
GraphPad Prism (versions 7.0.4 and 8.0.2) built-in tests were used to analyze the data provided. For the boxplots and growth inhi-
bition curves, data are the mean average of 3 independent experiments and error bars are represented as ± SEM (unless otherwise
noted). p values are indicated on the graphs and the absolute values are denoted in the figure legends. All data presented are normal-
ized to their respective vehicle control. Technical and biological replicates are as indicated in the figure legends.
ImageJ Software
ImageJ (version 2.0.0) software was used to analyze images (Schneider et al., 2012).
SynergyFinder
Bliss synergy scores were calculated using SynergyFinder (version 1.6.1) R (version 3.5.1) package (Ianevski et al., 2017) as
described in ‘‘Proliferation assays.’’
Decision Tree and Forest Analyses
Decision tree and forest analyses were performed by using Sci-Kit Learn (version 0.20.3) in Python (version 3.6.3). RPPA dataset was
grouped into five categories: vehicle control versus RAFi, vehicle control versus ERKi, vehicle control versus RAFi + ERKi, RAFi
versus RAFi + ERKi, and ERKi versus RAFi + ERKi. RPPA dataset was further grouped into two categories as training and test
data. Training (70% of RPPA dataset) and test data (remining 30% of RPPA dataset) comprise equal distribution of samples from
the five categories described above. Decision trees were generated by using these training and test data. Accuracy for decision trees
was above 80%.
For decision forest analysis, 70% of the data from each of the five categories (described above) were fit to a decision forest by a
RandomGrid Search to optimize for the best fitting forest based on F1macro score (number of estimators between 300 and 500 and
max features between 30 and 150). Once a model was obtained, accuracy on the test set was accessed (greater than 90% for all
categories) and feature importance’s from the model were used to rank the most critical proteins.
CRISPR Analysis
CRISPR sequencing was performed at UNC (High-Throughput Sequencing Facility, Chapel Hill, NC) and Hudson Alpha
(HudsonAlpha Genomic Services Laboratory, Huntsville, AL). Single-end sequencing (75 bp) was performed by using Illumina
NextSeq 500 with 10% PhiX (varied depending on the run). Read counts for individual samples were quantified using the protocol
outlined in Shalem et al. (2014). Briefly, unaligned reads in FASTQ format were used to generate a Burrows-Wheeler index using the
Bowtie build-index function. Reads were then aligned to the index using the Bowtie aligner, followed by the quantification of the num-
ber of reads per sgRNA. For each pair of samples (vehicle control and drug treated), guide constructs were removed if they were not
identified in the vehicle control. Missing values in the treated samples were imputed with the mean value of all guide constructs for
that gene in the treated sample. Reads were then normalized between samples by converting them to a percentage of total reads per
sample. The ratio of vehicle/treated for each construct yielded an ‘‘enrichment ratio’’ for the pair of samples per guide construct. To
summarize results per gene, the average enrichment ratio (AER) was calculated for each gene among all constructs. Genes with a
standard deviation in enrichment ratio greater than three were removed. Genes were rank ordered by their AER and assigned to bins
according to their position in the ranked list. Genes were then given a value according to their bin assignment: top 10% sensitizerse8 Cell Reports 31, 107764, June 16, 2020
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excluding top 10% (bin value = 1), neither sensitizer nor antagonizer (bin value = 0). Given the variability of genetic CRISPR-Cas9
screens (between samples and replicates), this bin placement method permitted greater comparability between sample pairs.
DSRT Chemical Library Screen Analysis
Inhibitors included in the screen were categorized by their known primary protein target (Gautam et al., 2016; Pemovska et al., 2013;
Yadav et al., 2014). Cell lines and drugs were hierarchically clustered using average linkage and Euclidean distance; dDSS values are
displayed.
Reverse phase protein array (RPPA) analysis
Antibody intensity values were imported into R (version 3.5.2) andmissing values were imputedwith themedian intensity value for the
respective antibody. Data were log2 transformed and the fold change over the median vehicle value was calculated for each anti-
body, factored by cell line and time point. Euclidean distance and average linkage were utilized for semi-supervised hierarchical clus-
tering of log2 fold-change values for antibodies.
RNA Sequencing Analysis
Counts data were imported into R (version 3.5.2) and differential expression analysis was performed with the DESeq2 package
(version 1.22.2) (Liberzon et al., 2015, 2011; Love et al., 2014; Mootha et al., 2003; Subramanian et al., 2005). Significant hits were
defined by an adjusted p value < 0.05. Gene set enrichment analysis (GSEA) was performed using the GSEA Desktop application
(version 3.0, available at https://www.gsea-msigdb.org/gsea/index.jsp) and curated gene sets were obtained from MSigDB (v6.2,
available at https://www.gsea-msigdb.org/gsea/msigdb/index.jsp). Specific gene sets are referenced in figure legends.
GSEAPreranked was run using the DESeq2 test statistic as the weighted ranking factor for each comparison.
MIB/MS Analysis
Following MaxQuant processing of data and generation of Label-free quantification (LFQ) intensity values, data files were analyzed
using R (version 3.5.2). A total of 207 kinases were identified with 191 present in > 50% of samples and containing two or more pep-
tides. 27/191 kinases were missing one or more values after this filtering and these values were imputed. A normal distribution was
modeled on the non-missing LFQ intensity values of the kinases containing missing intensity values. Imputed values were drawn
randomly from this distribution. Following filtering and imputation, LFQ intensity values were log2 transformed and the fold change
over the median vehicle value was calculated for each kinase. significant kinases between DMSO, ERKi, RAFi, and ERKi+RAFi treat-
ments were determined using one-way ANOVA (Benjamini-Hochberg adjusted p value < 0.05). Euclidean distance and average link-
age were utilized for unsupervised hierarchical clustering of log2 fold-change values for significant kinases.
Tumor Xenograft Statistical Analysis
The statistical analysis of the tumor volume data begins with a data transformation to a log scale to equalize variance across time and
treatment groups. The log volume data are analyzed with a two-way repeated-measures analysis of variance by time and treatment
using the MIXED procedures in SAS software (Version 9.3). The correlation model for the repeated-measures is Spatial Power.
Treated groups are compared to the control group at each time point. The MIXED procedure is also used separately for each treat-
ment group to calculate adjusted means and standard errors at each time point. Both analyses account for the autocorrelation within
each animal and the loss of data that occurs when animals with large tumors are removed from the study early. The adjusted means
and standard errors (s.e.) are plotted for each treatment group versus time. Analysis for tumor volume is based on log10 and spatial
power covariance structure. P value is based on the comparison between two specific groups.
Tumor Xenograft Combination Analysis Method (Bliss independence)
First, the usual repeated-measures model is fit to log volume versus group and time. Then contrast statements are used to test for an
interaction effect at each time point using the 2 specific treatments that are combined. This is equivalent to the Bliss Independence
method and assumes that tumor volumes can, in theory, reach zero, i.e., complete regression. The expected additive response (EAR)
for the combination is calculated on the tumor volume scale as: response (EAR) EAR volume = V1 * V2/V0, where V0, V1, and V2 are
the estimated mean tumor volumes for the vehicle control, treatment 1 alone, and treatment 2 alone, respectively. If the interaction
test is significant, the combination effect is declared statistically more than additive or less than additive depending on the observed
combination mean volume being less than or more than the EAR volume, respectively. Otherwise, the statistical conclusion is addi-
tive. In addition, a biologically relevant range of additivity can be defined as X% above and below the EAR volume. Typically, X would
be 25 to 40%. Then a biological conclusion can be made for the combination as synergistic (greater than additive), additive, or less
than additive if the observed combination mean volume is below, in, or above the interval of additivity.
There may be situations were stasis is the best expected response. In those situations, the Bliss method can be applied directly to
the%delta T/C values to obtain an EAR percent response: EAR%delta T/C = Y1 * Y2/100, where Y1 andY2 are the percent delta T/C
values for the single-agent treatments. Currently, there is no statistical test to compare the observed% delta T/C in the combination
group versus the EAR, but the biological criterion described above can be applied.Cell Reports 31, 107764, June 16, 2020 e9
